A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of NWRD08 in Patients With HPV16/18-Positive Cervical High-Grade Squamous Intraepithelial Lesion (HSIL)
Latest Information Update: 20 Feb 2026
At a glance
- Drugs NWRD-08 (Primary)
- Indications Human papillomavirus infections
- Focus Therapeutic Use
- Sponsors Newish Technology (Beijing)
Most Recent Events
- 17 Feb 2026 Status changed from not yet recruiting to recruiting.
- 19 Sep 2025 New trial record